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Leukocyte arrest at target endothelial sites is 
nearly exclusively mediated by integrin recep-
tors (1). As circulating leukocytes maintain their 
integrins in a generally nonadhesive state, a 
key checkpoint in leukocyte arrest is the rapid 
modulation of integrin affi   nity and avidity to 
endothelial ligands (2) by various agonists, pre-
dominantly chemoattractants or chemokines, 
presented on the endothelium (3, 4). Likewise, 
platelets maintain their major fi  brinogen receptor, 
the integrin αIIbβ3, in an inactive conforma-
tion, which is converted by multiple agonists, 
predominately ligands to G protein–coupled 
receptors (GPCRs), into an activated recep-
tor with high affi   nity to multiple ligands (5). 
The small GTPase Rap-1 has been implicated 
in the activation of leukocyte, platelet, and 
megakaryocyte integrins by multiple receptors, 
including GPCRs, the TCR, receptors to vari-
ous infl  ammatory cytokines, and shear stress 
signals (6–13).
We recently described a human genetic de-
fi  ciency of leukocyte adhesion to endothelium 
leukocyte adhesion defi  ciency (LAD) III that is 
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Leukocyte and platelet integrins rapidly alter their affi  nity and adhesiveness in response 
to various activation (inside-out) signals. A rare leukocyte adhesion defi  ciency (LAD), 
LAD-III, is associated with severe defects in leukocyte and platelet integrin activation. 
We report two new LAD cases in which lymphocytes, neutrophils, and platelets share 
severe defects in β1, β2, and β3 integrin activation. Patients were both homozygous for a 
splice junction mutation in their CalDAG-GEFI gene, which is a key Rap-1/2 guanine 
exchange factor (GEF). Both mRNA and protein levels of the GEF were diminished in LAD 
lymphocytes, neutrophils, and platelets. Consequently, LAD-III platelets failed to aggre-
gate because of an impaired αIIbβ3 activation by key agonists. β2 integrins on LAD-III 
neutrophils were unable to mediate leukocyte arrest on TNFα-stimulated endothelium, 
despite normal selectin-mediated rolling. In situ subsecond activation of neutrophil β2 
integrin adhesiveness by surface-bound chemoattractants and of primary T lymphocyte 
LFA-1 by the CXCL12 chemokine was abolished. Chemokine inside-out signals also failed 
to stimulate lymphocyte LFA-1 extension and high affi  nity epitopes. Chemokine-triggered 
VLA-4 adhesiveness in T lymphocytes was partially defective as well. These studies iden-
tify CalDAG-GEFI as a critical regulator of inside-out integrin activation in human 
T lymphocytes, neutrophils, and platelets.
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distinct from LAD-I. Whereas LAD-I is a genetic defect in 
β2 integrin expression or function (14), LAD-III leukocytes 
express intact integrins with an impaired ability to generate 
high avidity to their endothelial ligands at vascular endothelial 
contacts in response to rapid endothelial chemoattractant sig-
nals (15, 16). Patient leukocytes, however, express function-
ally intact GPCRs. A role for Rap-1 malfunction in the 
LAD-III syndrome was inferred by our fi  nding that LAD-III 
lymphoblasts express normal levels of Rap-1, which fails to 
undergo activation in response to the prototypic chemokine 
CXCL12. Although Rap-1 is also implicated in the survival 
and function of many nonhematopoietic tissues (17–19), no 
severe developmental disorders or abnormalities in nonhe-
matopoietic tissues were reported in the LAD-III patients 
(14). Thus, we suggested that LAD-III and related integrin 
activation defects in hematopoietic systems are the result of a 
loss in a key Rap-1 guanine exchange factor (GEF) that is es-
sential for the transduction of leukocyte and platelet GPCR 
signals into Rap-1 and integrin activation.
In this study, we report two similar LAD-III cases in 
which neutrophil and lymphocyte integrins cannot acquire 
adhesiveness upon rapid activation by GPCR agonists under 
shear fl  ow conditions. Chemokine-induced activation of 
two LFA-1 conformations associated with integrin exten-
sion and high affi   nity states is also largely impaired in LAD-III 
T lymphocytes. In addition, platelets derived from the two 
patients fail to aggregate in response to prototypic inside-out 
signals, and their key integrin, αIIbβ3, does not acquire a high 
affi   nity state essential for ligand binding and aggregation. 
These LAD cases share a homozygous mutation in the ac-
ceptor splice junction at the beginning of exon 16 of the 
Rap-1 GEF, CalDAG-GEFI (RasGRP2). Furthermore, LAD-
derived total blood levels of CalDAG-GEFI mRNA and 
the protein expression in LAD platelets, neutrophils, and lym-
phocytes are diminished. These results are the fi  rst example 
of a human inherited disease caused by a Rap GEF defi  -
ciency that is linked to profound defects in both leukocyte 
and platelet integrin activation and adhesive functions in 
the vasculature.
RESULTS
Patients
The two patients, a 1-yr-old male (patient K) and a 2-yr-old 
female (patient A) of Turkish origin were each born to 
consanguineous parents. The two families, although not 
related, originally lived in the close villages in the eastern 
region of Turkey, suggesting a common ancestor. Both sets 
of parents are asymptomatic. Both patients shared a similar 
clinical presentation consisting of petechia from birth 
caused by a severe bleeding tendency and requiring re-
peated blood transfusions. They suff  ered recurrent and se-
vere bacterial infections associated with marked leukocytosis 
(25–70,000/mm3, 60% neutrophils and 30% lymphocytes), 
but normal platelet counts. More than 95% of patient neu-
trophils expressed CD18, CD11a, and CD11b integrins, 
ruling out a LAD-I syndrome. Lymphocyte subsets and 
immunoglobulin levels were within normal range. Patient 
A suff  ered from recurrent severe pneumonias, necessitating 
constant antibiotic treatment. Patient K suff  ered from re-
current severe pneumonias and sepsis. He had surgery to 
correct a bowel intususception when he was 14 mo old, 
resulting in a large, nonhealing wound after the operation. 
Blood culture yielded B-hemolytic Pseudomonas aeruginosa. 
Patient K died at 2 yr of age from sepsis and pulmonary 
bleeding. Laboratory data showed hemoglobin around 8 gr%. 
Failure to thrive was consistent in both patients from early 
life, and both children were below the fi  fth percentile 
for both height and weight. Patient A’s sister died at age 
15 mo from pneumonia and sepsis and had suff  ered from 
anemia and bleeding tendency from early life. Patient A 
has only one healthy brother aged 6 yr. Patient K does not 
have siblings. Neither of the patients displayed overt neuro-
logical disorders.
Platelets derived from LAD patients fail to aggregate 
because of the inability of agonists to trigger high 
affi  nity 𝗂IIb𝗃3
As both patients displayed major bleeding disorders in addi-
tion to their severe leukocytosis, we fi  rst analyzed their agonist-
stimulated platelet aggregation. Platelet aggregation triggered 
by all GPCR agonists tested, i.e., ADP, epinephrine, arachi-
donic acid, and thrombin, was completely absent in patient-
derived platelets (Fig. 1 A and not depicted), despite only 
moderate reduction in surface αIIbβ3 (GpIIbβ3) expression 
(Fig. 1 B, inset). As this integrin is the main fi  brinogen recep-
tor on platelets (5), these results suggested a major defect 
in GPCR-mediated inside-out activation of patient αIIbβ3 
(Fig. 1 A). An alternative GPCR-independent inside-out 
  activation pathway that stimulates αIIbβ3-mediated platelet 
aggregation involves the binding of collagen to platelet 
receptors such as GPVI and the α2β1 integrin (20). Patient-
derived platelets were also unable to aggregate in response to 
collagen signals (Fig. 1 A). However, these multiple defects 
were not caused by a global platelet aggregation defect be-
cause when GPCR signaling to αIIbβ3 was bypassed with the 
vWF agonist ristocetin, patient platelets underwent robust 
aggregation, although at a twofold lower magnitude (Fig. 1 A). 
Defective platelet aggregation could result from a failure of 
αIIbβ3 to undergo activation or from cytoskeletal defects that 
impair postligand occupancy of this integrin (5). Direct acti-
vation by agonists of the αIIbβ3 integrin, from an inactive 
state to a fully active integrin with high affi   nity to ligands, 
can be probed by binding of the ligand mimetic activation 
reporter antibody, PAC-1 (21). PAC-1–specifi  c staining of 
activated platelets derived from the LAD patients was slightly 
reduced in response to platelet GPCR agonists, whereas 
PAC-1 staining on control platelets was dramatically increased 
(Fig. 1 B). In contrast, P- selectin was normally activated by 
the same agonists in LAD-derived platelets (unpublished 
data). These results collectively indicate that affinity up-
regulation of αIIbβ3 by inside-out signals is severely impaired 
in patient platelets.JEM VOL. 204, July 9, 2007  1573
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Absence of CalDAG-GEFI transcripts and protein in LAD 
patient-derived platelets and neutrophils
The Rap-1 GEF CalDAG-GEFI has been implicated as a key 
regulator of agonist-induced αIIbβ3 activation and platelet aggre-
gation (22). Therefore, we analyzed the level of CalDAG-GEFI 
by RT-PCR in total blood. Strikingly, several CalDAG-
GEFI transcripts tested were nearly completely absent from 
blood obtained from both patients (Fig. 2 A and not depicted), 
whereas normal levels of this transcript were found in all four 
parents (Fig. 2 A). In contrast, levels of a second Rap-1 GEF, 
CalDAG-GEFIII, were completely normal in both patients 
compared with parents and age-matched control (Fig. 2 A). 
Quantitative PCR analysis revealed that CalDAG-GEFI was 
expressed at >30-fold lower levels in LAD patient A com-
pared with healthy age-matched control, whereas the expres-
sion level of CalDAG-GEFIII was comparable (Fig. 2 B). In 
agreement with the loss of CalDAG-GEFI in LAD patients, 
Western blot analysis with two mAbs against CalDAG-GEFI 
revealed a complete loss of the protein in lysates derived from 
platelets and neutrophils purifi  ed from patient A (Fig. 2 C 
and not depicted). Consistent with the RT-PCR results, 
both of patient A’s parents expressed normal levels of the 
CalDAG-GEFI protein in both neutrophil and platelet lysates 
(unpublished data).
Both LAD patients share an identical homozygous mutation 
in an intronic acceptor splice junction in CalDAG-GEFI
We next assessed whether the two patients were homozy-
gous at the CalDAG-GEFI chromosomal locus 11q13.1. 
We identifi  ed a single microsatellite marker, located at 
chr11:64,428,757-64,429,006 (National Center for Biotech-
nology Information build 36), which is 159,253 bp away from 
the gene (chr11:64,250,960-64,269,504), and thus the closest 
published polymorphic marker to CalDAG-GEFI. We ini-
tially used this marker to analyze DNA of the two patients, 
their parents, and the healthy sibling of patient A (Fig. 3 A). 
In family A, two alleles, 252 and 260 bp long, were detected 
in the samples derived from the parents. Patient A was homo-
zygous for the 260-bp allele, whereas his healthy sibling was 
homozygous for the 252-bp allele. In family K, DNA from 
both parents contained two alleles that were 248 and 260 bp 
in lengths, whereas patient K was homozygous for the 260 bp 
allele. These results indicated that the two patients are each 
homozygous for the same aff  ected allele, which suggested that 
this allele may carry a mutation for CalDAG-GEFI.
We next sequenced the genomic region of CalDAG-
GEFI from 2,000 bp upstream to 500 bp downstream of the 
cDNA sequence (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20070058/DC1). 20 deviations from 
the reference genome were found, comprising 17 known single-
nucleotide polymorphisms (SNPs) and 3 novel SNPs (Fig. S2). 
The PCR products containing novel SNPs were generated 
and sequenced in LAD patient A’s healthy brother. Only one 
novel SNP, IVS15nt718c>a, was unique in LAD patient A 
(Fig. 3 B and Fig. S3). The same mutation was found in LAD 
patient K (Fig. 3 B and Fig. S3). Importantly, this mutation 
was absent in all 116 control chromosomes tested from Turkish 
donors (unpublished data). The mutation occurs 3 bp up-
stream of the beginning of exon 16, disrupting the splice 
junction present at that location. An automated splice site 
Figure 1.  GPCR and collagen agonists fail to trigger LAD-III–
derived platelet aggregation caused by their inability to trigger high 
affi  nity 𝗂IIb𝗃3 integrin. (A) Platelet aggregation induced by GPCR agonists, 
collagen, and the vWF agonist ristocetin. Figures depict treatments at 
time 0 of either healthy control (black line) or LAD patient K (gray line) 
platelets with epinephrine (fi  rst panel), arachidonic acid (second panel), 
collagen (third panel), or ristocetin (fourth panel), as indicated in the 
Materials and methods. (B) FACS staining of resting (gray line) and agonist-
stimulated (black line) platelets derived from a healthy (age-matched) 
donor and LAD patient K with the αIIbβ3 ligand mimetic mAb PAC-1. Verti-
cal lines depict the mean intensity of background staining with an 
  isotype-matched control mAb. Small graphs depict the total surface 
αIIbβ3 levels on these stimulated platelets. Similar results were obtained 
with LAD patient A.1574  GENETIC DISORDER IN INTEGRIN ACTIVATION | Pasvolsky et al.
analysis program based on information theory (23) was used 
to predict the possible eff  ects of this mutation on splicing. The 
program predicts that this mutation creates a putatively active 
cryptic splice site located 1 bp before the actual site, which is 
concomitantly weakened (Fig. S4). If this cryptic site is pre-
ferred by the transcription machinery, the products of such a 
splice would have a shifted reading frame and a premature 
stop codon, resulting in nonsense-mediated decay (NMD) 
(24). Collectively, the LAD patients share a homozygous mu-
tation in a critical acceptor splice region of CalDAG-GEFI 
that predicts the loss of message, which was indeed observed 
(Fig. 2, A and B).
CalDAG-GEFI–null neutrophils fail to arrest on infl  amed 
endothelial cells and on ICAM-1 in spite of normal 
selectin-mediated capture and rolling
Neutrophils from the initial LAD-III patient characterized by 
us (15) expressed normal levels of the two major β2 integrins 
implicated in neutrophil arrest on vascular endothelium, 
LFA-1 and Mac-1. Neutrophils derived from the two new 
LAD cases also expressed normal levels of LFA-1 and Mac-1 
(Fig. 4 A and not depicted). The LAD-derived CalDAG-GEFI–
null neutrophils were next perfused over a monolayer of  TNF-
stimulated human umbilical vein endothelial cells (HUVECs) 
under physiological shear fl  ow; these cells express high levels 
of E-selectin and multiple β2 integrin ligands (25, 26). Patient 
and control neutrophils were captured by the cytokine-activated 
HUVEC at comparable rates and initiated normal rolling 
on the endothelial monolayer (Fig. 4 B). Shortly after capture 
on the endothelial surface, normal neutrophils spontaneously 
arrest on the activated endothelium, in a β2 integrin–de-
pendent manner (26) (unpublished data), whereas CalDAG-
GEFI–null neutrophils failed to arrest and continued to roll 
over the cytokine-activated EC monolayer (Fig. 4 B), as was 
previously observed for LAD-III neutrophils (15). Inhibition 
of phospholipase C (PLC) in control neutrophils completely 
eliminated their ability to arrest in a β2 integrin–dependent 
manner on the activated HUVECs (unpublished data), which 
is consistent with a role for PLC, an upstream regulator of 
CalDAG-GEFI (22) in CalDAG-GEFI–mediated β2 integrin 
activation in normal neutrophils. Furthermore, whereas both 
normal and LAD neutrophils were effi   ciently captured by 
Figure 2.  Loss of CalDAG-GEFI mRNA and protein in blood samples 
of two LAD patients. (A) CalDAG-GEFI amplified by RT-PCR from 
peripheral blood DNA derived from patients A and K and their parents 
using the primers listed in Fig. S1. Levels of CalDAG-GEFIII and actin tran-
scripts are shown as controls. The data shown are representative of fi  ve 
independent experiments. (B) Relative CalDAG-GEFI and CalDAG-GEFIII 
mRNA expression levels were determined by Q-RT-PCR in LAD patient A (L) 
and an age-matched control (C). GusB was used for normalization for 
each gene, and normalization to HRPT1 gave similar results. The data are 
representative of three independent experiments. (C) Western blot analy-
sis of platelet and neutrophil lysates derived from an age-matched con-
trol donor and LAD patient. CalDAG-GEFI (CDGI) levels were probed using 
the mAb 18B11. Left columns depict CalDAG-GEFI levels in wt and 
CalDAG-GEFI knockout murine platelets probed with the same mAb. Actin 
levels are shown as control. 
Figure 3.  Both LAD patients are homozygous for a c>a mutation 
in a splice junction of the CalDAG-GEFI gene. (A) A microsatellite 
marker containing 11.75 TATC perfect repeats located on chromosome 
11q13.1, which is located 159,253 bp away from the CalDAG-GEFI gene, 
was amplifi  ed in single plex reaction by touchdown PCR using genomic 
DNA prepared from the patients (A and K), their parents, and one healthy 
sibling from family A, as well as from an unrelated control family. The 
separated fl  uorescently labeled PCR products were analyzed using GeneScan 
analysis software. The allele length distribution in each detected indi-
vidual is shown. (B) Multiple alignment of genomic DNA surrounding the 
putative disease-causing mutation. The reference genome (National Center 
for Biotechnology Information 36; chr11:64253078-64253108), the mRNA 
(NM_005825), and genomic sequence from the patients, their parents, 
and one healthy sibling were aligned surrounding the mutation (in bold). 
Note that M is the IUPAC-IUB ambiguity code for A or C. The full trace 
alignments are depicted, in color, in Fig. S3.JEM VOL. 204, July 9, 2007  1575
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E-selectin coimmobilized with ICAM-1 (Fig. 4 C), nearly 
all normal neutrophils either immediately arrested on the 
E-selectin/ICAM-1 surface or rolled for several seconds before 
arrest, but none of the LAD neutrophils were able to arrest 
(Fig. 4 C). Exclusion of Mg2+ from the binding medium 
  resulted in integrin inactivation and loss of arrest on the 
E-selectin/ICAM-1 surface only in control neutrophils (Fig. 
4 C). As expected, this integrin inactivation did not aff  ect the 
capture and rolling adhesions initiated by either control or 
LAD neutrophils. These results collectively indicate intact 
rolling capacity, but loss of adhesiveness of both LFA-1 and 
Mac-1 integrins in LAD neutrophils interacting with infl  amed 
endothelial cells, as well as with purifi  ed ICAM-1 under shear 
fl  ow conditions.
Impaired spontaneous 𝗃2 integrin adhesiveness to ICAM-1 
in CalDAG-GEFI–null neutrophils is associated with reduced 
levels of high affi  nity integrin conformations
The inability of both LFA-1 and Mac-1 expressed by LAD 
neutrophils to develop fi  rm adhesions could result from im-
proper inside-out activation through E-selectin (27, 28). We 
therefore next compared β2-mediated attachments of normal 
and LAD neutrophils to isolated ICAM-1 coated at high 
density in the absence of E-selectin. Control blood-derived 
neutrophils retained moderate levels of spontaneous β2 inte-
grin adhesiveness to high density ICAM-1, manifested by the 
ability of these leukocytes to generate both transient and fi  rm 
tethers on the ligand under low shear fl  ow (Fig. 5 A). Nota-
bly, β2 integrins on LAD-derived CalDAG-GEFI–null neu-
trophils failed to interact with ICAM-1 even under these 
permissive fl  ow conditions (Fig. 5 A). Furthermore, pro-
longed association with ICAM-1 under static conditions 
allowed β2 integrins on normal, but not on LAD, neutrophils 
to generate high shear–resistant adhesions (Fig. 5 B). Thus, a 
considerable fraction of normal neutrophils settled on ICAM-1 
for 1 min developed resistance to detachment by high shear 
stress, whereas only a negligible fraction of LAD neutrophils 
developed shear resistance on ICAM-1 after prolonged 
  association with the ligand under static conditions (Fig. 5 B). 
These results suggested that LAD β2 integrins are inherently 
defective in their acquisition of the intermediate and/or 
high affi   nity states necessary for rapid ligand recognition and 
contact-dependent adhesion strengthening on ligands (29, 30). 
Comparing the levels of these β2 conformational states probed 
by specifi  c reporter mAbs, we found, however, identical lev-
els of the β2 integrin extension reporter KIM127 on both 
normal and LAD neutrophils (Fig. 5 C, top). Nevertheless, 
the appearance of the high affi   nity 327C β2 I domain epitope 
on LAD β2 integrins was reduced by fi  vefold (Fig. 5 C, bot-
tom), which is consistent with defective acquisition of high 
affi   nity states by LAD β2 integrins.
Mac-1 in CalDAG-GEFI–null leukocytes fails to undergo 
subsecond activation of adhesiveness by chemoattractants
In a previous study on LAD-III neutrophils, we found that 
the neutrophil Mac-1 could undergo normal conformational 
activation by chemoattractants, but failed to respond to in 
situ inside-out stimulation by the same surface-bound che-
moattractants under shear fl  ow (15). To directly assess in the 
present LAD syndrome the ability of Mac-1 to undergo inside-
out activation by prototypic chemoattractants, we next assessed 
whether platelet-activating factor (PAF) can alter the integrin 
activation state in patient neutrophils. CBRM1/5 is a ligand 
mimetic mAb that detects high affi   nity Mac-1 subsets (31). 
Figure 4.  Firm 𝗃2-mediated adhesion, but not capture or rolling, 
are defective in LAD neutrophils. (A) FACS staining of LFA-1 and Mac-1 
integrins on control and LAD patient A neutrophils using the mAbs 
TS2.4 (anti-αL integrin subunit) and CBRM1/2 (anti-αM integrin subunit), 
respectively. Background antibody stainings had fl  uorescence intensity 
values of <5. (B) Neutrophil accumulation and development of fi  rm ar-
rest on TNFα-activated HUVECs under physiological shear fl  ow. Healthy 
age-matched donor (control) or patient A (LAD) neutrophils were perfused 
for 1 min at 0.75 dyn/cm2 over the HUVEC monolayers, and accumulated 
leukocytes were subjected to a shear stress of 5 dyn/cm2 for a 10-s period. 
The number of adherent leukocytes that either continued to roll on the 
monolayer or came to full arrest immediately or after a short period of 
rolling (RA, rolling then arrest) was determined during the 10-s period. 
The values shown correspond to fractions of the original leukocyte fl  ux in 
immediate contact with the endothelial layer. (C) Frequency and type of 
tethers generated by control and LAD (patient A) neutrophils interacting 
with 0.2 μg/ml E-selectin-Fc coimmobilized with 5 μg/ml ICAM-1-Fc on a 
protein A–coated surface. Neutrophils were perfused at 1.5 dyn/cm2 over 
the substrate either in the presence of Ca2+ alone (Ca) or in regular bind-
ing medium containing both Ca2+ and Mg2+ (CaMg), and the frequencies 
of each of the indicated tethers were determined. Results in B and C are 
each representative of three independent experiments. Data represent the 
mean ± the range of two fi  elds of view. Similar results were obtained in 
LAD patient K.1576  GENETIC DISORDER IN INTEGRIN ACTIVATION | Pasvolsky et al.
In contrast to platelets, PAF, as well as IL-8, eff  ectively trig-
gered the CBRM1/5 Mac-1 neoepitope in patient CalDAG-
GEFI–null neutrophils, which is consistent with normal PAF 
and IL-8 signaling in these cells (Fig. 6 A and not depicted). 
Nevertheless CalDAG-GEFI–null neutrophils failed to mount 
any PAF- or IL-8–dependent in situ activation of their Mac-1 
when perfused over fi  brinogen coimmobilized with these 
chemokines (Fig. 6 B). The ability of IL-8 to trigger LAD 
neutrophil attachments to ICAM-1, which is a shared ligand of 
Mac-1 and LFA-1 (32), was also abrogated (Fig. 6 C). Notably, 
neutrophils from the patient’s mother, although confi  rmed to be 
a heterozygote carrier of the mutated gene (Fig. 3 and Fig. S3), 
expressed normal levels of CalDAG-GEFI protein (not depicted) 
and underwent comparable in situ activation of Mac-1 by 
IL-8 (Fig. 6 B). This suggests that one normal allele is suffi   -
cient for full protein expression and function. As expected, 
neutrophils from the healthy sibling, who was a confi  rmed 
homozygote for the two normal CalDAG-GEFI alleles (Fig. 3 
and Fig. S3), were indistinguishable from healthy neutro-
phils in all adhesion assays tested (not depicted). Collec-
tively, these results suggest that β2 integrins in LAD-  derived, 
CalDAG-GEFI–null neutrophils are completely defective 
in their ability to undergo rapid, chemoattractant-triggered 
activation under shear stress conditions, despite retained 
chemoattractant-triggered conformational activation of their 
Mac-1 β2 integrin.
Abolished chemokine activation of LFA-1 and of VLA-4–
mediated arrest in CalDAG-GEFI–defi  cient LAD lymphocytes
Murine splenocytes express negligible levels of CalDAG-
GEFI (Fig. 7 A) (22). Strikingly, high levels of the GEF were 
found in primary freshly isolated T lymphocytes from healthy 
donors (Fig. 7 A). As CalDAG-GEFI was completely lost in 
primary LAD T lymphocytes (Fig. 7 A), we next assessed how 
the GEF defi  ciency aff  ects the function of the two major 
lymphocyte integrins, the β2 integrin LFA-1 and the β1 inte-
grin VLA-4. LAD lymphocytes expressed both integrins, as 
well as CXCR4, which is the main receptor for the proto-
typic lymphocyte chemokine CXCL12 (SDF-1α) at normal 
levels (Fig. 7 B). Nevertheless, CXCL12-mediated activation 
of LFA-1, assessed by the induction of the integrin extension 
epitope KIM127, as well as the high affi   nity integrin confor-
mation, probed by the 327C mAb (33), was greatly reduced 
in LAD-derived, CalDAG-GEFI–defi   cient T lymphocytes 
(Fig. 7 C). In agreement with defective chemokine-induced 
inside-out activation of LFA-1 in CalDAG-GEFI–defi  cient 
lymphocytes, CXCL12 failed to trigger any LFA-1 adhesions 
to ICAM-1 under shear fl  ow (Fig. 7 D). Thus, CalDAG-
GEFI is critical for CXCL12-mediated inside-out activation 
of LFA-1 in primary human T cells. We next assessed the 
role of CalDAG-GEFI in chemokine-mediated activation of 
VLA-4 in T cells interacting with VCAM-1 and coimmobi-
lized CXCL12 under shear fl  ow. In healthy T lymphocytes, 
this prototypic chemokine triggers robust VLA-4–dependent 
lymphocyte tethering, rolling, and arrest on VCAM-1 under 
shear fl  ow (25). Notably, VLA-4 of patient CalDAG-GEFI–
null T lymphocytes could still undergo in situ activation by 
CXCL12 (Fig. 7 E), but CXCL12-triggered VLA-4 failed 
to arrest patient CalDAG-GEFI–null T lymphocytes on 
VCAM-1. These data suggest that CalDAG-GEFI is only 
partially required for inside-out activation of VLA-4. As 
VLA-4 activation epitopes are not induced in T lymphocytes 
by soluble CXCL12 (25), and there are no available VLA-4 
ligand mimetic mAbs, we could not confi  rm an inside-out 
defect in chemokine-triggered VLA-4 conformation or affi   n-
ity state based on activation epitope analysis, as we could for 
LFA-1 (Fig. 7 C). We could rule out a defect in outside-in 
activation of VLA-4 by VCAM-1 because CalDAG-GEFI–null 
Figure 5.  Reduced levels of spontaneous 𝗃2 integrin adhesiveness 
and 𝗃2 activation states in LAD neutrophils. (A) β2 integrin–mediated 
capture and arrest on ICAM-1 are defective in LAD (patient A) neutrophils. 
The categories of the different type of adhesive tethers (transient or 
  arrest) measured at a shear stress of 0.5 dyn/cm2 are expressed as the 
percentage of the total neutrophils in direct contact with the indicated 
ICAM-1–coated substrates. Low and high density ICAM-1–coated fi  elds 
(380 and 1,900 sites/μm2, respectively) were prepared by overlaying 1 and 
5 μg/ml of ICAM-1-Fc, respectively, on protein A precoated at 1 and 
20 μg/ml. (B) Spontaneous β2-mediated neutrophil adhesion to the high 
density ICAM-1 depicted in A developed upon 1-min static contact. 
Level and strength of adhesion were determined by the relative resistance 
of either healthy (age-matched) or LAD neutrophils to detachment by the 
indicated incremented shear stresses. Results in A and B are representa-
tive of four independent experiments. (C) Basal expression of the β2 ex-
tension epitope KIM127 (top) and the β2 I-like domain activation epitope 
327C (bottom) on either control or LAD (patient A) neutrophils analyzed 
by FACS staining. Background antibody stainings had fl  uorescence inten-
sity values of <5. Results are given as the mean ± the range of determi-
nations in two fi  elds of view, and the experiment shown is representative 
of three independent determinations. Similar results were obtained in 
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T lymphocytes arrested normally on high density VCAM-1 
(unpublished data). Our data collectively suggest a defect in 
chemokine stimulation of high avidity VLA-4 bonds critical 
for immediate adhesion strengthening and lymphocyte arrest 
on VCAM-1 under shear stress conditions.
D  I  S  C  U  S  S  I  O  N 
Integration of calcium and DAG signals triggered by PLC 
is a common theme shared by many biological targets, in-
cluding immunoreceptors and integrins (34). Although these 
two second messengers can promote integrin adhesiveness 
via their cooperative activation of classical protein kinase C 
family members (35), chemokine activation of leukocyte 
integrins takes place independently of this kinase family (7, 
25, 30). Alternative eff  ectors triggered by DAG and calcium 
are members of the CalDAG-GEF/RasGRP family, but the 
importance of these GEFs in leukocyte integrin activation 
just begins to unfold (36). In mice, a Rap-1/2 and R-Ras–
specifi  c GEF, CalDAG-GEFI, was recently implicated in 
  integrin activation underlying platelet aggregation, fi  brinogen 
binding, and thrombus formation (22). Genetic ablation of 
CalDAG-GEFI results in severely compromised integrin-
dependent platelet aggregation and bleeding disorders (22), 
but the role of this or other Rap-1 GEFs in leukocyte integrin 
activation has been vague.
We now report the fi  rst human genetic adhesion disorder 
that is associated with an aberrant expression of this GEF in 
lymphocytes, neutrophils, and platelets. In agreement with data 
on murine platelets derived from CalDAG-GEFI knockout 
mice (22), patient-derived platelets that lack CalDAG-GEFI 
exhibit major defects in both GPCR- and collagen-induced 
platelet aggregation, as well as in GPCR-triggered αIIbβ3 ac-
tivation. We also provide the fi  rst indication for a key role 
of CalDAG-GEFI in neutrophil and lymphocyte integrin 
activation by various chemoattractant signals under shear stress 
conditions relevant for leukocyte interactions with blood ves-
sels. Our genetic analysis has identifi  ed a homozygous muta-
tion in the acceptor splice junction at the beginning of exon 
16 of the CalDAG-GEFI gene in both LAD patients. Famil-
ial segregation analysis also indicates that the patients’ parents 
are heterozygous for this mutation, yet they are healthy and 
their leukocytes express normal levels of the GEF. Thus, we 
establish for the fi  rst time an autosomal recessive mutation in 
a LAD-III syndrome. Furthermore, this is a fi  rst implication 
of a single Rap-1 GEF as a critical inside-out regulator of 
integrin activation in two major types of human leukocytes 
and platelets.
 The role of CalDAG-GEFI in lymphocyte integrin acti-
vation has been obscure because this GEF was not detected 
in the white pulp of the murine spleen or in the thymus (22). 
We confi  rmed these results, but found considerable expres-
sion of the protein in healthy human peripheral blood T cells. 
Because primary LAD T cells lacked this GEF, we were 
prompted to dissect the contribution of CalDAG-GEFI to 
rapid chemokine-induced integrin activation in T lymphocytes. 
Chemokine activation of lymphocyte integrins involves 
simultaneous bidirectional activation by both inside-out 
and outside-in rearrangements in integrin headpieces and tails 
(37, 38). Choosing CXCL12 as a prototypic chemokine for 
lymphocyte integrin activation (39), we assessed the ability 
of both LFA-1 and VLA-4 in CalDAG-GEFI–null LAD 
T lymphocytes to undergo in situ stimulation of adhesiveness 
under physiological conditions of shear fl  ow. Because integ-
rin tethers form within leukocyte contacts with integrin li-
gands in the range of 0.04–0.1 s (25, 30), any immediate 
adhesive tethers in situ stimulated by the surface-bound che-
mokine involves the contact of the integrin and the GPCR 
with their cognate ligands in this short time frame. Our re-
sults therefore indicate an indispensable role for CalDAG-
GEFI in the earliest stages (i.e., subsecond-lived contacts) 
Figure 6.  Chemoattractants fail to trigger Mac-1 adhesiveness 
in LAD neutrophils at subsecond contacts. (A) Normal PAF-triggered 
induction of the activation Mac-1 neoepitope CBRM1/5 on LAD (patient A) 
neutrophils. Control or LAD neutrophils were either left intact (−) or 
stimulated with 100 nM PAF (+). Background antibody stainings had 
fl  uorescence intensity values of <5. (B) Capture and arrest of neutrophils 
on low density fi  brinogen (coated at 0.5 μg/ml) coated alone or in the 
presence of immobilized 100 nM PAF or 2 μg/ml IL-8. Control or LAD neu-
trophils were perfused over the substrates at a shear stress of 0.5 dyn/cm2. 
Analysis of neutrophils derived from patient’s mother and analyzed 
on identical substrates is included. Results are given as the mean ± the 
range. The data shown are representative of three experiments. (C) Cap-
ture and arrest of neutrophils on ICAM-1 coated at 5 μg/ml alone or in 
the presence of 2 μg/ml IL-8. Analysis was conducted as in B. The experi-
ment shown is representative of three. In B and C, the number of leuko-
cytes transiently or stably interacting with the substrate was determined 
in two fi  elds of view and expressed in frequency units as in Figs. 4 and 5. 
The experiment shown is representative of three. Similar results were 
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of chemokine-induced LFA-1 fi  rm adhesiveness. Correspond-
ingly, we also fi  nd this GEF to be essential for the triggering 
in T cells of two conformational states of LFA-1 associated 
with integrin extension and high affi   nity to ligand (30). 
Furthermore, VLA-4 in CalDAG-GEFI–null T cells also fails 
to develop high avidity binding to its major endothelial 
  ligand VCAM-1 in response to in situ activation signals from 
CXCL12, although a signifi   cant fraction of VLA-4 on 
CalDAG-GEFI–null lymphocytes could still undergo normal 
in situ activation by CXCL12 at subsecond contacts. Impor-
tantly, α4 integrin conformations can be regulated by shear 
forces without noticeable changes in integrin affi   nity to ligand 
under shear-free conditions (40, 41). Interestingly, the subset 
of fi  rm arrest-mediating VLA-4–VCAM-1 tethers developed 
by healthy, but not by GEF-defi  cient, T cells is sensitive to 
inhibition by low levels of soluble VLA-4 ligands known to 
selectively block high affi   nity VLA-4 (25). Although VLA-
4–mediated adhesions require proper integrin anchorage to 
the cytoskeleton, we have ruled out a VLA-4 anchorage de-
fect in LAD T cells because these cells normally tethered and 
arrested on high density VCAM-1 (unpublished data). Nev-
ertheless, we cannot exclude the possibility that defective 
VLA-4–mediated T cell arrest in LAD T cells is caused by a 
failure of chemokine-activated VLA-4 to anchor to the cyto-
skeleton and develop optimal shear resistance in CalDAG-
GEFI–defi  cient T cells. The GEF is dispensable, however, 
for chemokine-triggered VLA-4–mediated transient and 
rolling adhesions, which are generally mediated by low or 
intermediate affi   nity VLA-4 subsets (64). We thus conclude 
that T cells lacking CalDAG-GEFI undergo incomplete 
chemokine-triggered activation of VLA-4, suggesting that 
unlike LFA-1, VLA-4 regulation by chemokines involves 
additional and redundant CalDAG-GEFI–independent sig-
nal  ing pathways.
A fi  nal step in integrin activation is the binding of the cyto-
skeletal adaptor talin to integrin tails (42). A novel integrin 
activation pathway, which links inside-out signals to αIIbβ3 
affi   nity modulation via a Rap-1–RIAM–talin signaling com-
plex was recently identifi  ed (43). It is likely that CalDAG-
GEFI acts upstream of this complex not only in platelets (20, 
22) but also in neutrophils and lymphocytes. Neutrophil 
Rap-1 is strongly activated by cytosolic calcium and by 
Figure 7.  Defective chemokine triggering of LFA-1– and VLA-4–
mediated PBL arrest on ICAM-1 and VCAM-1. (A) Western blot analy-
sis of T lymphocyte lysates derived from a C57BL mouse, a healthy donor 
(control), and LAD patient A (LAD). CalDAG-GEFI (CDGI) levels were probed 
with an anti–CalDAG-GEFI mAb (top). Actin levels are shown as controls 
(bottom). (B) FACS staining of LFA-1, VLA-4, and CXCR4 on control and 
LAD PBLs using the αL subunit–specifi  c mAb TS2.4, the α4 subunit-specifi  c 
mAb HP1.2, and 12G5, respectively. (C) LFA-1 extension epitope detected 
by the reporter mAb KIM127 (top row) and high affi  nity LFA-1 epitope 
detected by the mAb 327C (bottom row) in intact (−) and CXCL12-treated 
(+) control and LAD PBLs, assessed by FACS staining. Background anti-
body stainings in B and C had fl  uorescence intensity values of <5. 
(D) Tethering and immediate arrest of control (left) and LAD (right) PBLs 
on ICAM-1-Fc (coated at 2 μg/ml) triggered by immobilized CXCL12 
(2 μg/ml). Control or LAD PBLs were perfused over the substrates at a shear 
stress of 0.5 dyn/cm2, and both the frequency and strength of all tethers 
were determined in two fi  elds. Results are given as the mean ± the range. 
All adhesive tethers were blocked in the presence of the LFA-1 blocking 
mAb, TS1.18, or EDTA. The experiment shown is representative of three. 
(E) Tethering and arrest of control and LAD PBLs measured at a shear stress 
of 0.5 dyn/cm2 on sVCAM-1 (coated at 2 μg/ml) triggered by immobilized 
CXCL12 (2 μg/ml). The lifetimes of the transient tethers are depicted 
above the bars. All tethers were blocked in the presence of the VLA-4 
blocking mAb HP1.2, or the low mol wt ligand, Bio1211 (not depicted). The 
different tether categories were determined as in D.JEM VOL. 204, July 9, 2007  1579
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phorbolester DAG analogues (44), implicating these two sec-
ondary messengers and their key regulatory enzyme, PLC, in 
Rap-1 activation of neutrophil integrins. Indeed, β2-mediated 
neutrophil arrest on infl  amed endothelium is highly sensitive 
to inhibition of PLC (unpublished data). Rap-1 is found in 
multiple membranal pools in various cell types (45), but its 
activation by GPCRs occurs mainly in the plasma membrane 
(46, 47). Because these signals are transmitted within a frac-
tion of a second at leukocyte–endothelial contacts (48), at 
least on circulating cells, CalDAG-GEFI and its immediate 
targets are expected to preexist near the plasma membrane in 
proximity to their target integrins. CalDAG-GEFI may also 
activate integrins by triggering the small GTPase R-Ras, 
which was previously implicated in affi   nity modulation of the 
β1 integrin VLA-5 (49). It is noteworthy that, apart from the 
loss of CalDAG-GEFI, we did not fi  nd any expression defect 
in either Rap-1 or talin in patient platelets and leukocytes 
(unpublished data). The involvement of CalDAG-GEFI in 
platelet, neutrophil, and lymphocyte integrin activation sug-
gests that some of the previously published clinical studies of 
integrin activation defects in leukocytes and platelets (50–53) 
may involve defi  ciency in this key GEF. With the exception 
of RAPL, none of the aforementioned Rap-1 eff  ectors are 
specifi  c to hematopoietic cells; thus, a genetic defect in any of 
these eff  ectors would not be restricted to the hematopoietic 
lineage, in contrast to the LAD-III defect described here. In-
deed, the loss of CalDAG-GEFI in LAD patient blood did 
not appear to impair any Rap-1–related functions in nonhe-
matopoietic cellular environments; although the two patients 
exhibited dense bone in x-ray scans, this is apparently caused 
by impaired migration of bone remodeling precursors into 
their skull tissues (54). Similar to the phenotype of our pa-
tients, CalDAG-GEFI–null mice do not display any severe 
nonhematopoietic-associated disorder (22).
It is quite surprising that the loss of CalDAG-GEFI in 
platelets and leukocytes could not be compensated by any 
other Rap-1 activating GEF. Leukocytes and platelets express 
multiple Rap-1 GEFs in addition to CalDAG-GEFI, including 
CalDAG-GEFIII, the receptor tyrosine kinase–stimulated GEF 
C3G, and the cAMP-triggered GEF EPAC (17, 55). EPAC is 
expressed at very low levels in neutrophils (53), and thus can-
not serve as a major Rap1 GEF in these cells. Importantly, we 
detected comparable levels of the two other Rap1 GEFs, 
CalDAG-GEFIII and C3G (Fig. 2 B and not depicted), in 
LAD neutrophils and lymphocytes, which suggest that these 
Rap-1 GEFs cannot functionally compensate for a loss of 
CalDAG-GEFI. Future studies will be required to address this 
point. Another open question is whether defi  ciency  in 
CalDAG-GEFI in murine neutrophils results in a similarly dra-
matic loss of integrin inside-out activation under the experi-
mental conditions studied in the present work. Lastly, although 
this Rap-1 GEF is missing in murine lymphocytes, Rap-1 ac-
tivation is considered as important in murine integrin regula-
tion as it is in human integrin regulation (56). If so, one should 
expect to fi  nd in murine lymphocytes an alternative Rap-1 
GEF that is critical for lymphocyte integrin activation.
In addition to regulating inside-out integrin activation in 
platelets, neutrophils, and lymphocytes, Rap-1 and CalDAG-
GEFI may also control critical outside-in activation steps, im-
posed by ligand-induced rearrangements (2, 57). Indeed, in 
the present work, as well as in a study on neutrophils from a 
previous LAD-III patient (15), the Mac-1 integrin could un-
dergo normal inside-out activation in the presence of the pro-
totypic chemoattractant PAF, but still failed to generate 
adhesiveness in response to rapid PAF signals under shear stress 
conditions, suggesting a defect in outside-in integrin activation 
of this integrin. Recent studies suggest that without proper 
anchorage to the cytoskeleton and a series of rearrangements 
of the β2 integrin LFA-1 by its ligand during subsecond con-
tacts, this integrin, and possibly other integrins operating at 
leukocyte–endothelial contacts, may fail to generate shear-
resistant adhesiveness (30). Rearrangement of integrins by their 
ligands transduces specifi  c cytoplasmic changes in integrin tails 
(58), which may be stabilized by in situ GPCR-mediated 
Rap-1 activation (16). Indeed, inhibition of Rap-1 by over-
expression of its GAP, SPA-1, can interfere with integrin adhe-
siveness, even when the integrin ectodomain is artifi  cially 
stabilized at a high affi   nity state by Mn2+ or by activating mAbs 
(59), which is consistent with a major role of Rap-1, and po-
tentially of CalDAG-GEFI, in outside-in integrin activation. 
Rap-1 is also implicated in diverse signaling pathways that link 
shear stress signals to integrin activation in various cell types 
(12, 60). Future studies will need to address these multiple 
potential roles of CalDAG-GEFI as an integrator of both inside-
out and outside-in integrin activation events in diff  erent neu-
trophil and lymphocyte subsets.
MATERIALS AND METHODS
Reagents and mAbs. Recombinant ICAM-1-IgG1 and E-selectin-IgG1 
fusion protein, as well as human SDF-1α (CXCL12) and CXCL8 (IL-8), were 
purchased from R&D Systems. Recombinant soluble seven-domain human 
VCAM-1, sVCAM-1 (61), was a gift from R. Lobb (Biogen, Cambridge, MA). 
BSA (fraction V), Ca2+, and Mg2+-free HBSS, EGTA, Hepes, fi  brinogen, 
and Ficoll-Hypaque 1077 were obtained from Sigma-Aldrich. Human serum 
albumin (fraction V) was purchased from Calbiochem. The anti–β2 integrin 
subunit mAb TS1.18, the anti–LFA-1 TS2.4, and the anti–Mac-1 integrin 
mAbs CBRM1/2 and CBRM1/5 (62) were gifts from T. Springer (Harvard 
University, Boston, MA). The Alexa Fluor 488–conjugated anti–β2 integ-
rin neoepitope 327C mAb (33) was a gift from D. Staunton (ICOS Corpora-
tion, Bothell, WA). The KIM127 mAb (68) was a gift from M.K. Robinson 
(UCB Celltech, Slough, UK). The FITC-labeled antiactivated αIIbβ3 mAb 
PAC-1 was purchased from Becton Dickinson. Anti–P-selectin mAb and 
the anti-αIIbβ3 mAb were both purchased from Immunotech Coulter. 
Polyclonal goat anti-actin antibody (sc-1616) was purchased from Santa 
Cruz Biotechnology.
Platelet isolation and aggregation studies.  Informed consent was obtained 
from each individual studied. This study was approved by the Institutional 
Review Board of the Rambam Medical Center, which is consistent with the 
provisions of the Declaration of Helsinki. Citrated blood was centrifuged at 150 g 
for 10 min at RT, and platelet-rich plasma was isolated (63). Platelets were ad-
justed to a concentration of 3 × 108/ml with 1/10 volume of 3.2% buff  ered 
sodium citrate. Aggregation was initiated by adding 5 μM ADP, 10 μM epi-
nephrine, 10 μg/ml arachidonic acid, 2 μg/ml collagen, or 1.25 mg/ml ristocetin. 
Aggregation was monitored by light transmission using a two-channel aggrego-
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Isolation and culture of leukocytes. Human peripheral blood neutro-
phils and T lymphocytes were isolated from citrate-anticoagulated whole 
blood, as previously described (25, 64). Murine T lymphocytes were purifi  ed 
from C57BL/6 splenocytes, as previously described (65). Murine platelets 
were isolated and purifi  ed from wild-type and CalDAG-GEFI knockout 
mice, as previously described (22). Leukocytes were stored in cation-free 
HBSS containing 10 mM Hepes, pH 7.4, and 2 mg/ml BSA at room tem-
perature for up to 2 h before experimentation.
RT-PCR analysis.  RNA prepared from EDTA-anticoagulated peripheral 
blood was extracted using the RNeasy mini kit (QIAGEN). cDNA was 
synthesized using random hexamer primers (Promega) with Superscript II 
RNase H-negative reverse transcriptase (Invitrogen). cDNA was amplifi  ed 
by PCR using specifi  c primers, which are listed in Fig. S1. QRT-PCR was 
performed as previously described (66), using a LightCycler (Roche) accord-
ing to the manufacturer’s instructions. PCR reactions were performed 
in duplicate. PCR amplifi  cation consisted of 35–50 cycles of denaturation, 
annealing, and extension. Denaturation was performed for 15 s at 95°C, an-
nealing was performed at 60°C, and the extension was performed at 72°C for 
20 s, with fl  uorescence detection at 72°C after each cycle. After the fi  nal cycle, 
melting point analyses of all samples were performed within the range of 
62–99°C. Expression levels of GusB and of HPRT1 were used for sample 
normalization. A standard curve was obtained with serial dilutions of a refer-
ence cDNA sample amplifi  ed concomitantly with the tested samples. 
CalDAG-GEFI and CalDAG-GEFIII mRNA levels were determined by 
comparing experimental levels to the standard curves and are expressed as 
arbitrary units. The primers used are listed in Fig. S1.
Microsatellite analysis.  Blood was drawn and DNA was isolated by stan-
dard methods. PCR amplifi  cation of one microsatellite marker with a maxi-
mal length of 260 bp, which contained 11.75 TATC perfect repeats and was 
located 159,253 bp upstream of CALDAG-GEFI on the minus strand on 
chromosome 11q13.1, was performed in single plex reaction by touchdown 
PCR (MJ Research). Two primers, fl  anking the microsatellite marker, were 
used in the reaction, one of which was fl  uorescently labeled: forward PCR 
primer, Fam-C  G  C  C  G  A  G  A  C  A  T  A  T  A  A  A  C  A  C  C  C  ; reverse PCR primer, 
A  C  T  T  G  A  A  T  C  T  G  G  G  A  G  G  C  G  . PCR products were separated on a 16-
capillary automated genetic analyzer (AB 3100; Applied Biosystems). Results 
were analyzed using the GeneScan analysis software (AB 3100).
DNA sequencing. The full CalDAG-GEFI gene, including the 2,000-bp 
region upstream of the fi  rst exon and the 500-bp region downstream of the 
last exon (chr11:64,250,405-64,271,447), were PCR amplifi  ed, and 90% of 
these segments were successfully sequenced in LAD patient A as previously 
described (67). The primers used for each segment are listed in Fig. S1. Prim-
ers of fragment 32 (Fig. S1) were used to amplify the region containing the 
IVS15nt718c>a mutation, and thus were subsequently used to screen the 
genomic DNA of LAD patient K, the healthy brother of LAD patient A, 
the 4 parents of both patients, and 58 Turkish control donors. Sequence analysis 
was performed using Sequencher Version 4.7 (Gene Codes Corporation).
Flow cytometry.  Leukocyte surface staining was performed and analyzed 
by FACScan, as previously described (64). For analysis of neutrophil expres-
sion of the Mac-1 activation neoepitope CBRM1/5, washed neutrophils 
were either left intact or stimulated with agonists for 10 min at 37°C, in the 
presence of the appropriate reporter mAb. Cells were washed at 4°C, stained 
with PE-conjugated secondary Ab (Jackson ImmunoResearch Laboratories), 
and FACScan analysis was performed as previously described (15). Sponta-
neous β2 integrin activation was assayed by incubating the intact leukocytes 
with the reporter mAbs 327C (33) or KIM127 (68) for 10 min at 37°C, fol-
lowed by secondary staining. CXCL12-induced activation of these epitopes 
was assayed in T lymphocytes as previously described (29). Activation of 
αIIbβ3 was measured on washed platelets incubated with 1.0 μg/ml ADP and 
1.0 μg/ml epinephrine or control buff  er in the presence of 10 μg/ml of 
FITC-labeled PAC-1 mAb (21).
Western blot analysis. For Western blot analysis, platelet, neutrophil, hu-
man lymphocyte, or murine lymphocyte lysates were fi  rst centrifuged at 13,000 
rpm for 20 min at 4°C before their protein concentrations were determined. 
Lysates were applied to a 7.5% SDS-PAGE under reducing conditions and 
then transferred to a nitrocellulose membrane. Cell lysis, gel electrophoresis, 
and transfer to membranes were performed as previously described (41). The 
membrane was blocked and reacted overnight at 4°C with either monoclonal 
anti–CalDAG-GEFI antibody 18B11 (69), polyclonal rabbit anti–CalDAG-
GEFI antibody 3753 (22), or polyclonal goat anti-actin control antibodies 
(Santa Cruz Biotechnology). After several washes, the membrane was probed 
with appropriate secondary IgG conjugated to horseradish peroxidase (Jackson 
ImmunoResearch Laboratories), and developed by ECL reaction.
Preparation of adhesive substrates and HUVEC monolayers. Prepara-
tion of substrates for the laminar fl  ow adhesion assays were performed as previ-
ously described (64, 70). In brief, ICAM-1-Fc–coated substrates were prepared 
by plating polystyrene dishes with 1 μg/ml protein A, followed by coimmobi-
lization of either heat-inactivated (−) or intact (+) chemokines and human 
serum albumin, each at 2 μg/ml. The protein A-chemokine substrates were 
overlaid overnight at 4°C with the indicated concentrations of ICAM-1-Fc. 
sVCAM-1 was coimmobilized with CXCL12 (both at 2 μg/ml), as previously 
described (25). E-selectin/ICAM-1 substrates were prepared by coating 
0.2 μg/ml E-selectin-Fc on high density protein A, followed by ICAM-1-Fc 
coating (5 ng/ml). Neutrophil arrests on this substrate were totally blocked by 
pretreatment with the β2 integrin–blocking mAb TS1.18. Fibrinogen was 
coated directly at 0.5 μg/ml and washed, and PAF (Sigma-Aldrich) was over-
laid at 100 nM for an additional hour. PAF was verifi  ed to potently activate 
neutrophil integrins via their PAF receptors (26). For adhesion experiments on 
resting or TNFα-activated endothelial cells, primary HUVECs (passage 2 or 3) 
were left intact or stimulated for 18 h with heparin-free culture media supple-
mented with TNFα (2 ng/ml, 100 U/ml; R&D Systems) (70).
Analysis of leukocyte attachments and resistance to detachment 
  developed during short, static contacts.  All shear fl  ow experiments were 
performed at 37°C. Neutrophils and T lymphocytes were suspended in binding 
medium (cation-free HBSS, containing 10 mM Hepes, pH 7.4, and 2 mg/ml 
BSA supplemented with Ca2+ and Mg2+ at 1 mM each) and immediately per-
fused through the chamber at controlled fl  ow rates, as previously described (25). 
All cellular interactions with the adhesive substrates were determined by a 
MatLab-based computerized tracking of individual cell motion within at least 
two fi  elds of view (each 0.17 mm2 in area). “Transient” tethers were defi  ned 
as cells attached briefl  y (<2 s) to the substrate; “rolling tethers” were attached 
cells that persistently rolled for at least 2 s over the substrate; “rolling then ar-
rested” were cells that stopped for at least 3 s after a rolling period; “arrest 
(fi  rm) tethers” were defi  ned as tethered cells that immediately stopped for at 
least 3 s (30). For analysis of integrin-mediated adhesion strengthening at short 
stationary contacts, leukocytes were perfused into the fl  ow chamber and al-
lowed to settle onto the substrate for 1 min. Flow was then initiated and in-
creased step-wise every 5 s through a programmed set of fl  ow rates. At the end 
of each 5-s interval, the number of cells that remained bound was expressed 
relative to the number of cells originally settled on the substrate.
Online supplemental material.  Fig. S1 shows the primers used for PCR am-
plifi  cation and sequencing of CalDAG-GEFI. Fig. S2 shows the polymorphisms 
found in the genomic sequencing. Note that all alleles refer to the minus strand. 
Fig. S3 depicts the sequence of the genomic DNA surrounding the putative 
mutation. The genomic DNA was amplifi  ed using primer set 32 (Fig. S1), and 
analyzed as described in Fig. 3. The base of the mutation is highlighted. Shown 
are the base alignment (left) and the trace alignment (right). Fig. S4 shows splice 
site analysis using information theory (23). The online version of this article is 
available at http://www.jem.org/cgi/content/full/jem.20070058/DC1.
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